仑伐替尼+经肝动脉化疗栓塞+PD-1单抗治疗肝细胞癌合并门静脉主干癌栓和海绵样变(4例报道)  

Lenvatinib+transarterial chemoembolization+PD-1 antibody in the treatment of hepatocellular carcinoma with main portal vein tumor thrombus and cavernous transformation:four case reports

作　　者：张晓赟[1] 朱心睿 彭伟[1] 刘畅[1] 李川[1] 李秋[2] 陈卫霞[3] 李志平[4] 卢强[5] 卢武胜[1] 严律南[1] 杨家印[1] 文天夫[1] ZHANG Xiaoyun;ZHU Xinrui;PENG Wei;LIU Chang;LI Chuan;LI Qiu;CHEN Weixia;LI Zhiping;LU Qiang;LU Wusheng;YAN Lünan;YANG Jiayin;WEN Tianfu(Department of Liver Surgery/Liver Transplantation Center,West China Hospital,Sichuan University,Chengdu 610041,P.R.China;Department of Medical Oncology,Cancer Center,West China Hospital,Sichuan University,Chengdu 610041,P.R.China;Department of Radiology,West China Hospital,Sichuan University,Chengdu 610041,P.R.China;Department of Abdominal Radiotherapy,Cancer Center,West China Hospital,Sichuan University,Chengdu 610041,P.R.China;Department of Ultrasound,West China Hospital,Sichuan University,Chengdu 610041,P.R.China)

机构地区：[1]四川大学华西医院肝脏外科/肝移植中心,成都610041 [2]四川大学华西医院肿瘤中心腹部肿瘤科,成都610041 [3]四川大学华西医院放射科,成都610041 [4]四川大学华西医院肿瘤中心腹部放疗科,成都610041 [5]四川大学华西医院超声科,成都610041

出　　处：《中国普外基础与临床杂志》2022年第5期618-622,共5页Chinese Journal of Bases and Clinics In General Surgery

基　　金：四川省重点研发项目(项目编号:2020YFS0133);四川大学华西医院专职博士后研发基金(项目编号:2019HXBH004)。

摘　　要：目的总结仑伐替尼联合经肝动脉化疗栓塞(transarterial chemoembolization,TACE)及程序性死亡受体-1(programmed cell death protein-1,PD-1)单抗转化治疗肝细胞癌合并门静脉主干癌栓和海绵样变的效果。方法回顾性分析笔者所在医院收治的4例行仑伐替尼联合TACE及PD-1单抗转化治疗的肝细胞癌合并门静脉主干癌栓和海绵样变患者的临床资料。结果4例患者中2例获得完全缓解,2例获得部分缓解;肿瘤标志物均显著降低。但4例患者均未能接受手术切除。结论仑伐替尼联合TACE及PD-1单抗治疗肝细胞癌合并门静脉主干癌栓和海绵样变是有效的,但仍存在许多问题值得进一步探讨。Objective To summarize the effect of lenvatinib+transarterial chemoembolization(TACE)+programmed cell death protein-1(PD-1)antibody in the treatment of hepatocellular carcinoma with main portal vein tumor thrombus and cavernous transformation.Methods In this study,we reported the clinical data of four patients with hepatocellular carcinoma with main portal vein tumor thrombus and cavernous transformation who received conversion therapy with lenvatinib combined with TACE and PD-1 antibody in West China Hospital.Results Among the four patients,two patients achieved complete response and two achieved partial response;tumor markers were significantly decreased after combination treatment.However,all four patients failed to undergo hepatectomy.Conclusions Lenvatinib+TACE+PD-1 antibody is effective for hepatocellular carcinoma with main portal vein tumor thrombus and cavernous transformation.However,there are still many problems worthy of further discussion.

关 键 词：晚期肝细胞癌 门静脉主干癌栓 联合治疗 仑伐替尼 经肝动脉化疗栓塞 程序性死亡受体-1单抗 

分 类 号：R735.7[医药卫生—肿瘤]